SBIR/STTR Research Award
Long-read sequencing-based diagnosis for complex genomic and DNA methylation changes
Award amount
$313,372Program and phase
STTR · Phase IAward year
2025Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- D4Z4 MEDICINE, INC.
- Proposal award date
- 2025-08-07
- Contract end date
- 2026-07-31
- UEI
- PC6GTZFR4GY9
- Solicitation number
- PA23-232
- Topic code
- NCATS
Research abstract
PROJECT SUMMARY Structural changes in the genome and alterations of DNA methylation contribute to many diseases. Properly assessing these types of changes can be challenging using current technologies. One of the focuses of D4Z4 Medicine, Inc., is to provide long-read sequencing-based assays that can be used to determine structural variations and DNA methylation in one assay. In this proposal, we focus on a molecular diagnostic assay for facioscapulohumeral muscular dystrophy (FSHD). In addition to assay optimization, we will develop a user friendly and scalable data analysis tool, which will allow fast and accurate diagnostic report generation. In aim 1, we will standardize and validate the long-read sequencing assay. We will increase the capacity of the assay by adding additional target regions. We will also validate the assay using clinical samples. In aim 2, we will optimize a bioinformatics pipeline for analyzing long-read sequencing data containing D4Z4 repeat sequences and create a user-friendly interface. This approach developed here will provide a novel genetic diagnostic tool for FSHD which does not have an effective diagnostic tool. In addition, the assay and analysis tool will be expanded to cover additional genes and diseases.
Technology keywords
Not reported
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- A Novel Multi-Lineage Human Intestinal Organoid Screening Platform for Drug Discovery and Preclinical Testing
- A Novel Approach to Eliminate Length Impurities for High-Quality mRNA Production
- Development of CIL-0X: A Platform to Enhance Delivery of Inhaled RNA Therapeutics to Lung Cells
- Tethosomes: a non-viral DNA platform for durable expression of therapeutic transgenes in specific target cells
- Recombinant human enzymes for characterization of drug metabolism in US patient populations